Neuronetics, Inc. announced two peer-reviewed publications in the inaugural edition of the Transcranial Magnetic Stimulation journal. The first provides compelling evidence that transcranial magnetic Stimulation (TMS) induces universal improvement in depressive symptoms. The second paper demonstrates the superior sensitivity of one widely used depression assessment (the Patient Health Questionnaire-9, or PHQ-9) over another (the Quick Inventory of Depressive Symptomatology: Self-Report, or QIDS-SR) for measuring TMS outcomes. The following publications highlight key findings about the impact and assessment of TMS therapy: The Profile of Symptom Change with Transcranial Magneticstimulation for Major Depressive Disorder; About the publication: This analysis explores how TMS influences individual depressive symptoms in a cohort of 578 patients diagnosed with major depressive disorder (MDD).
By providing robust evidence of TMS's effectiveness and actionable insights for clinicians, Neuronetics continues to lead the charge in transforming depression treatment.
